Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 December 2020Website:
http://coeptistx.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 28 Oct 2024 20:00:01 GMTDividend
Analysts recommendations
Institutional Ownership
COEP Latest News
WEXFORD, Pa. , Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allogeneic natural killer (NK) cell technology.
Bolsters Company's Corporate Mission Financing Led by Board Member and Priced at Premium to Market Price WEXFORD, Pa. , June 20, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on $4.3 million in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise.
Coeptis Therapeutics (NASDAQ: COEP ) stock is climbing higher on Monday despite a lack of news from the drug company. Investors searching for the reason why COEP stock is up today won't find much news.
What type of business is Coeptis Therapeutics?
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology. The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
What sector is Coeptis Therapeutics in?
Coeptis Therapeutics is in the Healthcare sector
What industry is Coeptis Therapeutics in?
Coeptis Therapeutics is in the Biotechnology industry
What country is Coeptis Therapeutics from?
Coeptis Therapeutics is headquartered in United States
When did Coeptis Therapeutics go public?
Coeptis Therapeutics initial public offering (IPO) was on 17 December 2020
What is Coeptis Therapeutics website?
https://coeptistx.com
Is Coeptis Therapeutics in the S&P 500?
No, Coeptis Therapeutics is not included in the S&P 500 index
Is Coeptis Therapeutics in the NASDAQ 100?
No, Coeptis Therapeutics is not included in the NASDAQ 100 index
Is Coeptis Therapeutics in the Dow Jones?
No, Coeptis Therapeutics is not included in the Dow Jones index
When was Coeptis Therapeutics the previous earnings report?
No data
When does Coeptis Therapeutics earnings report?
The next expected earnings date for Coeptis Therapeutics is 08 November 2024